The DOI matches its Crossref record; 208 of the 208 references it cites were found in a registry or an index.
MLL-Rearranged Leukemias—An Update on Science and Clinical Approaches
Open accessAbstract
The Mixed-lineage leukemia 1 (MLL1) gene (now renamed Lysine [K]-specific MethylTransferase 2A or KMT2A) on chromosome 11q23 is disrupted in a unique group of acute leukemias. More than 80 different partner genes in these fusions have been described, although the vast majority of leukemias result from MLL1 fusions with one of about six common partner genes. Approximately 10% of all leukemias harbor MLL1 translocations. Of these, two patient populations comprise the majority of cases: patients younger than one year of age at diagnosis (primarily acute lymphoblastic leukemias), and young- to-middle-aged adults (primarily acute myeloid leukemias). A much rarer subgroup of patients with MLL1 rearrangements develop leukemia that is attributable to prior treatment with certain chemotherapeutic agents – so-called “therapy related leukemias”. In general, outcomes for all of these patients remain poor when compared to patients with non-MLL1 rearranged leukemias. In this review we will discuss the normal biological roles of MLL1 and its fusion partners, how these roles are hypothesized to be dysregulated in the context of MLL1 rearrangements, and the clinical manifestations of this group of leukemias. We will go on to discuss the progress in clinical management and promising new avenues of research which may lead to more effective targeted therapies for affected patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Acute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Yeoh, E.-J., Ross, M. E., Shurtleff, S. A., Williams, W. K., Patel, D., Mahfouz, R., Behm, F. G., Raimondi, S. C., Relling, M. V., Patel, A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00032-6 · Cited by 1,917
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
Armstrong, S. A., Staunton, J. E., Silverman, L. B., Pieters, R., den Boer, M. L., Minden, M. D., Sallan, S. E., Lander, E. S., Golub, T. R., & Korsmeyer, S. J. (2002) · Nature Genetics · doi:10.1038/ng765 · Cited by 1,723
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Controlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144
MLL Targets SET Domain Methyltransferase Activity to Hox Gene Promoters
Milne, T. A., Briggs, S. D., Brock, H. W., Martin, M. E., Gibbs, D., Allis, C. D., & Hess, J. L. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00741-4 · Cited by 1,053
DNA methyltransferase Dnmt1 associates with histone deacetylase activity
Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies, L., & Kouzarides, T. (2000) · Nature Genetics · doi:10.1038/71750 · Cited by 994
Tkachuk, D. C., Kohler, S., & Cleary, M. L. (1992) · Cell · doi:10.1016/0092-8674(92)90602-9 · Cited by 920
Altered Hox expression and segmental identity in Mll-mutant mice
Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A. J., & Korsmeyer, S. J. (1995) · Nature · doi:10.1038/378505a0 · Cited by 875
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Bernt, K. M., Zhu, N., Sinha, A. U., Vempati, S., Faber, J., Krivtsov, A. V., Feng, Z., Punt, N., Daigle, A., Bullinger, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.010 · Cited by 870
Self-citationGu, Y., Nakamura, T., Alder, H., Prasad, R., Canaani, O., Cimino, G., Croce, C. M., & Canaani, E. (1992) · Cell · doi:10.1016/0092-8674(92)90603-a · Cited by 824
hDOT1L Links Histone Methylation to Leukemogenesis
Okada, Y., Feng, Q., Lin, Y., Jiang, Q., Li, Y., Coffield, V. M., Su, L., Xu, G., & Zhang, Y. (2005) · Cell · doi:10.1016/j.cell.2005.02.020 · Cited by 804
Regulation of MLL1 H3K4 methyltransferase activity by its core components
Dou, Y., Milne, T. A., Ruthenburg, A. J., Lee, S., Lee, J. W., Verdine, G. L., Allis, C. D., & Roeder, R. G. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1128 · Cited by 763
Gardner, R., Wu, D., Cherian, S., Fang, M., Hanafi, L.-A., Finney, O., Smithers, H., Jensen, M. C., Riddell, S. R., Maloney, D. G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665547 · Cited by 749
Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
Daigle, S. R., Olhava, E. J., Therkelsen, C. A., Basavapathruni, A., Jin, L., Boriack-Sjodin, P. A., Allain, C. J., Klaus, C. R., Raimondi, A., Scott, M. P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-497644 · Cited by 722
Yokoyama, A., Somervaille, T. C. P., Smith, K. S., Rozenblatt-Rosen, O., Meyerson, M., & Cleary, M. L. (2005) · Cell · doi:10.1016/j.cell.2005.09.025 · Cited by 688
Pieters, R., Schrappe, M., De Lorenzo, P., Hann, I., De Rossi, G., Felice, M., Hovi, L., LeBlanc, T., Szczepanski, T., Ferster, A., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61126-x · Cited by 652
Menin Associates with a Trithorax Family Histone Methyltransferase Complex and with the Hoxc8 Locus
Hughes, C. M., Rozenblatt-Rosen, O., Milne, T. A., Copeland, T. D., Levine, S. S., Lee, J. C., Hayes, D. N., Shanmugam, K. S., Bhattacharjee, A., Biondi, C. A., et al. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00081-4 · Cited by 645
Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b
Kroon, E., Krosl, J., Thorsteinsdottir, U., Baban, S., Buchberg, A. M., & Sauvageau, G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.13.3714 · Cited by 640
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., Karaman, M. W., Pratz, K. W., Pallares, G., Chao, Q., et al. (2009) · Blood · doi:10.1182/blood-2009-05-222034 · Cited by 634
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614
Lin, C., Smith, E. R., Takahashi, H., Lai, K. C., Martin-Brown, S., Florens, L., Washburn, M. P., Conaway, J. W., Conaway, R. C., & Shilatifard, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.026 · Cited by 573
Tschiersch, B., Hofmann, A., Krauss, V., Dorn, R., Korge, G., & Reuter, G. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06693.x · Cited by 567
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells
Harris, W. J., Huang, X., Lynch, J. T., Spencer, G. J., Hitchin, J. R., Li, Y., Ciceri, F., Blaser, J. G., Greystoke, B. F., Jordan, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.014 · Cited by 566
Chemically ubiquitylated histone H2B stimulates hDot1L-mediated intranucleosomal methylation
McGinty, R. K., Kim, J., Chatterjee, C., Roeder, R. G., & Muir, T. W. (2008) · Nature · doi:10.1038/nature06906 · Cited by 563
Menin Critically Links MLL Proteins with LEDGF on Cancer-Associated Target Genes
Yokoyama, A., & Cleary, M. L. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.003 · Cited by 555
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Krivtsov, A. V., Feng, Z., Lemieux, M. E., Faber, J., Vempati, S., Sinha, A. U., Xia, X., Jesneck, J., Bracken, A. P., Silverman, L. B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.001 · Cited by 550
Leukemia in twins: lessons in natural history
Greaves, M. F., Maia, A. T., Wiemels, J. L., & Ford, A. M. (2003) · Blood · doi:10.1182/blood-2002-12-3817 · Cited by 543
Management Effectiveness of the World's Marine Fisheries
Mora, C., Myers, R. A., Coll, M., Libralato, S., Pitcher, T. J., Sumaila, R. U., Zeller, D., Watson, R., Gaston, K. J., & Worm, B. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000131 · Cited by 540
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target
Kisselev, A. F., van der Linden, W. A., & Overkleeft, H. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.01.003 · Cited by 527
Corral, J., Lavenir, I., Impey, H., Warren, A. J., Forster, A., Larson, T. A., Bell, S., McKenzie, A. N. J., King, G., & Rabbitts, T. H. (1996) · Cell · doi:10.1016/s0092-8674(00)81269-6 · Cited by 522
Meshinchi, S., Woods, W. G., Stirewalt, D. L., Sweetser, D. A., Buckley, J. D., Tjoa, T. K., Bernstein, I. D., & Radich, J. P. (2001) · Blood · doi:10.1182/blood.v97.1.89 · Cited by 518
The MLL recombinome of acute leukemias in 2013
Meyer, C., Hofmann, J., Burmeister, T., Gröger, D., Park, T. S., Emerenciano, M., Pombo de Oliveira, M., Renneville, A., Villarese, P., Macintyre, E., et al. (2013) · Leukemia · doi:10.1038/leu.2013.135 · Cited by 491
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias
for The St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project, Andersson, A. K., Ma, J., Wang, J., Chen, X., Gedman, A. L., Dang, J., Nakitandwe, J., Holmfeldt, L., Parker, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3230 · Cited by 490
Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors
Milne, T. A., Hughes, C. M., Lloyd, R., Yang, Z., Rozenblatt-Rosen, O., Dou, Y., Schnepp, R. W., Krankel, C., LiVolsi, V. A., Gibbs, D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408836102 · Cited by 469
Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
Grembecka, J., He, S., Shi, A., Purohit, T., Muntean, A. G., Sorenson, R. J., Showalter, H. D., Murai, M. J., Belcher, A. M., Hartley, T., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.773 · Cited by 462
In utero rearrangements in the trithorax-related oncogene in infant leukaemias
Ford, A. M., Ridge, S. A., Cabrera, M. E., Mahmoud, H., Steel, C. M., Chan, L. C., & Greaves, M. (1993) · Nature · doi:10.1038/363358a0 · Cited by 456
Trithorax group proteins: switching genes on and keeping them active
Schuettengruber, B., Martinez, A.-M., Iovino, N., & Cavalli, G. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3230 · Cited by 456
Balgobind, B. V., Raimondi, S. C., Harbott, J., Zimmermann, M., Alonzo, T. A., Auvrignon, A., Beverloo, H. B., Chang, M., Creutzig, U., Dworzak, M. N., et al. (2009) · Blood · doi:10.1182/blood-2009-04-215152 · Cited by 445
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 418
Pui, C.-H., Gaynon, P. S., Boyett, J. M., Chessells, J. M., Baruchel, A., Kamps, W., Silverman, L. B., Biondi, A., Harms, D. O., Vilmer, E., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08782-2 · Cited by 399
Armstrong, S. A., Kung, A. L., Mabon, M. E., Silverman, L. B., Stam, R. W., Den Boer, M. L., Pieters, R., Kersey, J. H., Sallan, S. E., Fletcher, J. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00003-5 · Cited by 398
A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification
Mueller, D., Bach, C., Zeisig, D., Garcia-Cuellar, M.-P., Monroe, S., Sreekumar, A., Zhou, R., Nesvizhskii, A., Chinnaiyan, A., Hess, J. L., et al. (2007) · Blood · doi:10.1182/blood-2007-05-090514 · Cited by 397
Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia
Strick, R., Strissel, P. L., Borgers, S., Smith, S. L., & Rowley, J. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070061297 · Cited by 390
Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain
Li, Y., Sabari, B. R., Panchenko, T., Wen, H., Zhao, D., Guan, H., Wan, L., Huang, H., Tang, Z., Zhao, Y., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.03.028 · Cited by 384
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
Zwaan, C. M., Kolb, E. A., Reinhardt, D., Abrahamsson, J., Adachi, S., Aplenc, R., De Bont, E. S. J. M., De Moerloose, B., Dworzak, M., Gibson, B. E. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8289 · Cited by 383
AF9 YEATS Domain Links Histone Acetylation to DOT1L-Mediated H3K79 Methylation
Li, Y., Wen, H., Xi, Y., Tanaka, K., Wang, H., Peng, D., Ren, Y., Jin, Q., Dent, S. Y. R., Li, W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.049 · Cited by 382
Yokoyama, A., Lin, M., Naresh, A., Kitabayashi, I., & Cleary, M. L. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.040 · Cited by 374
Global and Hox-specific roles for the MLL1 methyltransferase
Guenther, M. G., Jenner, R. G., Chevalier, B., Nakamura, T., Croce, C. M., Canaani, E., & Young, R. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503072102 · Cited by 357
The Pathogenesis of Mixed-Lineage Leukemia
Muntean, A. G., & Hess, J. L. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132434 · Cited by 344
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Kim, W., Bird, G. H., Neff, T., Guo, G., Kerenyi, M. A., Walensky, L. D., & Orkin, S. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 338
HOXA9 is required for survival in human MLL-rearranged acute leukemias
Faber, J., Krivtsov, A. V., Stubbs, M. C., Wright, R., Davis, T. N., van den Heuvel-Eibrink, M., Zwaan, C. M., Kung, A. L., & Armstrong, S. A. (2009) · Blood · doi:10.1182/blood-2007-09-113597 · Cited by 333
Döhner, K., Tobis, K., Ulrich, R., Fröhling, S., Benner, A., Schlenk, R. F., & Döhner, H. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.088 · Cited by 322
Super, H., McCabe, N., Thirman, M., Larson, R., Le Beau, M., Pedersen-Bjergaard, J., Philip, P., Diaz, M., & Rowley, J. (1993) · Blood · doi:10.1182/blood.v82.12.3705.3705 · Cited by 321
Unique and Independent Roles for MLL in Adult Hematopoietic Stem Cells and Progenitors
Jude, C. D., Climer, L., Xu, D., Artinger, E., Fisher, J. K., & Ernst, P. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.05.019 · Cited by 319
Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom)
Mohan, M., Herz, H.-M., Takahashi, Y.-H., Lin, C., Lai, K. C., Zhang, Y., Washburn, M. P., Florens, L., & Shilatifard, A. (2010) · Genes & Development · doi:10.1101/gad.1898410 · Cited by 313
Bitoun, E., Oliver, P. L., & Davies, K. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl444 · Cited by 312
Hilden, J. M. (2006) · Blood · doi:10.1182/blood-2005-07-3011 · Cited by 309
Lawrence, H. J., Helgason, C. D., Sauvageau, G., Fong, S., Izon, D. J., Humphries, R. K., & Largman, C. (1997) · Blood · doi:10.1182/blood.v89.6.1922 · Cited by 304
Yu, B. D., Hanson, R. D., Hess, J. L., Horning, S. E., & Korsmeyer, S. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10632 · Cited by 302
Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion.
Alexander, F. E., Patheal, S. L., Biondi, A., Brandalise, S. R., Cabrera, M. E., Chan, L., Chen, Z., Cimino, G. G., Córdoba, J. C., Gu, L. J., et al. (2001) · PubMed · Cited by 297
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Yamaguchi, T., Cubizolles, F., Zhang, Y., Reichert, N., Kohler, H., Seiser, C., & Matthias, P. (2010) · Genes & Development · doi:10.1101/gad.552310 · Cited by 291
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Jabbour, E., O'Brien, S., Konopleva, M., & Kantarjian, H. (2015) · Cancer · doi:10.1002/cncr.29383 · Cited by 285
Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia
Wei, J., Wunderlich, M., Fox, C., Alvarez, S., Cigudosa, J. C., Wilhelm, J. S., Zheng, Y., Cancelas, J. A., Gu, Y., Jansen, M., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.020 · Cited by 284
DOT1L, the H3K79 methyltransferase, is required for MLL-AF9–mediated leukemogenesis
Nguyen, A. T., Taranova, O., He, J., & Zhang, Y. (2011) · Blood · doi:10.1182/blood-2011-02-334359 · Cited by 275
Mll Has a Critical Role in Fetal and Adult Hematopoietic Stem Cell Self-Renewal
McMahon, K. A., Hiew, S. Y.-L., Hadjur, S., Veiga-Fernandes, H., Menzel, U., Price, A. J., Kioussis, D., Williams, O., & Brady, H. J. M. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.07.002 · Cited by 273
Hsieh, J. J.-D., Cheng, E. H.-Y., & Korsmeyer, S. J. (2003) · Cell · doi:10.1016/s0092-8674(03)00816-x · Cited by 271
Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential
Wong, P., Iwasaki, M., Somervaille, T. C. P., So, C. W. E., & Cleary, M. L. (2007) · Genes & Development · doi:10.1101/gad.1602107 · Cited by 266
MLL and CREB Bind Cooperatively to the Nuclear Coactivator CREB-Binding Protein
Ernst, P., Wang, J., Huang, M., Goodman, R. H., & Korsmeyer, S. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.7.2249-2258.2001 · Cited by 252
MLL-AF9-Induced Leukemogenesis Requires Coexpression of the Wild-Type Mll Allele
Thiel, A. T., Blessington, P., Zou, T., Feather, D., Wu, X., Yan, J., Zhang, H., Liu, Z., Ernst, P., Koretzky, G. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.034 · Cited by 248
Structural basis for activity regulation of MLL family methyltransferases
Li, Y., Han, J., Zhang, Y., Cao, F., Liu, Z., Li, S., Wu, J., Hu, C., Wang, Y., Shuai, J., et al. (2016) · Nature · doi:10.1038/nature16952 · Cited by 242
Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements
Pui, C.-H., Chessells, J. M., Camitta, B., Baruchel, A., Biondi, A., Boyett, J. M., Carroll, A., Eden, O. B., Evans, W. E., Gadner, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402883 · Cited by 241
Growth Disturbance in Fetal Liver Hematopoiesis of Mll-Mutant Mice
Yagi, H., Deguchi, K., Aono, A., Tani, Y., Kishimoto, T., & Komori, T. (1998) · Blood · doi:10.1182/blood.v92.1.108.413k11_108_117 · Cited by 238
Hsieh, J. J.-D., Ernst, P., Erdjument-Bromage, H., Tempst, P., & Korsmeyer, S. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.186-194.2003 · Cited by 234
MLL associates specifically with a subset of transcriptionally active target genes
Milne, T. A., Dou, Y., Martin, M. E., Brock, H. W., Roeder, R. G., & Hess, J. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503630102 · Cited by 230
Multiple Interactions Recruit MLL1 and MLL1 Fusion Proteins to the HOXA9 Locus in Leukemogenesis
Milne, T. A., Kim, J., Wang, G. G., Stadler, S. C., Basrur, V., Whitcomb, S. J., Wang, Z., Ruthenburg, A. J., Elenitoba-Johnson, K. S. J., Roeder, R. G., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.011 · Cited by 230
Zeleznik-Le, N. J., Harden, A. M., & Rowley, J. D. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10610 · Cited by 229
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy
Picaud, S., Fedorov, O., Thanasopoulou, A., Leonards, K., Jones, K., Meier, J., Olzscha, H., Monteiro, O., Martin, S., Philpott, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0236 · Cited by 229
Chen, C.-W., Koche, R. P., Sinha, A. U., Deshpande, A. J., Zhu, N., Eng, R., Doench, J. G., Xu, H., Chu, S. H., Qi, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3832 · Cited by 228
Self-citationXu, B., On, D. M., Ma, A., Parton, T., Konze, K. D., Pattenden, S. G., Allison, D. F., Cai, L., Rockowitz, S., Liu, S., et al. (2015) · Blood · doi:10.1182/blood-2014-06-581082 · Cited by 227
Positive feedback between NF-κB and TNF-α promotes leukemia-initiating cell capacity
Kagoya, Y., Yoshimi, A., Kataoka, K., Nakagawa, M., Kumano, K., Arai, S., Kobayashi, H., Saito, T., Iwakura, Y., & Kurokawa, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci68101 · Cited by 227
Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia
Rubnitz, J. E., Raimondi, S. C., Tong, X., Srivastava, D. K., Razzouk, B. I., Shurtleff, S. A., Downing, J. R., Pui, C.-H., Ribeiro, R. C., & Behm, F. G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.023 · Cited by 225
Slany, R. K., Lavau, C., & Cleary, M. L. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.1.122 · Cited by 224
Polycomb repressive complex 2 is required for MLL-AF9 leukemia
Neff, T., Sinha, A. U., Kluk, M. J., Zhu, N., Khattab, M. H., Stein, L., Xie, H., Orkin, S. H., & Armstrong, S. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202258109 · Cited by 224
Kawagoe, H., Humphries, R., Blair, A., Sutherland, H., & Hogge, D. (1999) · Leukemia · doi:10.1038/sj.leu.2401410 · Cited by 223
Birke, M. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.4.958 · Cited by 215
Interaction of MLL Amino Terminal Sequences with Menin Is Required for Transformation
Caslini, C., Yang, Z., El-Osta, M., Milne, T. A., Slany, R. K., & Hess, J. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2369 · Cited by 214
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia
Litzow, M. R., Tarima, S., Pérez, W. S., Bolwell, B. J., Cairo, M. S., Camitta, B. M., Cutler, C. S., de Lima, M., DiPersio, J. F., Gale, R. P., et al. (2010) · Blood · doi:10.1182/blood-2009-10-249128 · Cited by 213
Brown, P., Levis, M., Shurtleff, S., Campana, D., Downing, J., & Small, D. (2005) · Blood · doi:10.1182/blood-2004-06-2498 · Cited by 212
Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML
Krivtsov, A. V., Figueroa, M. E., Sinha, A. U., Stubbs, M. C., Feng, Z., Valk, P. J. M., Delwel, R., Döhner, K., Bullinger, L., Kung, A. L., et al. (2013) · Leukemia · doi:10.1038/leu.2012.363 · Cited by 203
Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia
Mueller, D., García-Cuéllar, M.-P., Bach, C., Buhl, S., Maethner, E., & Slany, R. K. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000249 · Cited by 203
Stam, R. W. (2002) · Blood · doi:10.1182/blood-2002-05-1600 · Cited by 203
Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation
Jo, S. Y., Granowicz, E. M., Maillard, I., Thomas, D., & Hess, J. L. (2011) · Blood · doi:10.1182/blood-2010-12-327668 · Cited by 199
Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias
So, C. W., Lin, M., Ayton, P. M., Chen, E. H., & Cleary, M. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00188-0 · Cited by 196
He, N., Chan, C. K., Sobhian, B., Chou, S., Xue, Y., Liu, M., Alber, T., Benkirane, M., & Zhou, Q. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107107108 · Cited by 194
NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases.
Sun, X.-F., & Zhang, H. (2007) · PubMed · doi:10.14670/hh-22.1387 · Cited by 188
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
Stam, R. W. (2005) · Blood · doi:10.1182/blood-2004-09-3667 · Cited by 185
Chromatin structural elements and chromosomal translocations in leukemia
Zhang, Y., & Rowley, J. D. (2006) · DNA Repair · doi:10.1016/j.dnarep.2006.05.020 · Cited by 182
Reaman, G. H., Sposto, R., Sensel, M. G., Lange, B. J., Feusner, J. H., Heerema, N. A., Leonard, M., Holmes, E. J., Sather, H. N., Pendergrass, T. W., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.445 · Cited by 179
Chen, Y.-X., Yan, J., Keeshan, K., Tubbs, A. T., Wang, H., Silva, A., Brown, E. J., Hess, J. L., Pear, W. S., & Hua, X. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510347103 · Cited by 175
Histone H3 Lysine 79 Methyltransferase Dot1 Is Required for Immortalization by MLL Oncogenes
Chang, M.-J., Wu, H., Achille, N. J., Reisenauer, M. R., Chou, C.-W., Zeleznik-Le, N. J., Hemenway, C. S., & Zhang, W. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3294 · Cited by 174
AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes
Deshpande, A. J., Deshpande, A., Sinha, A. U., Chen, L., Chang, J., Cihan, A., Fazio, M., Chen, C.-W., Zhu, N., Koche, R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.009 · Cited by 174
Self-citationVenetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Khaw, S. L., Suryani, S., Evans, K., Richmond, J., Robbins, A., Kurmasheva, R. T., Billups, C. A., Erickson, S. W., Guo, Y., Houghton, P. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707414 · Cited by 174
CBX8, a Polycomb Group Protein, Is Essential for MLL-AF9-Induced Leukemogenesis
Tan, J., Jones, M., Koseki, H., Nakayama, M., Muntean, A. G., Maillard, I., & Hess, J. L. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.008 · Cited by 172
Lavallée, V.-P., Baccelli, I., Krosl, J., Wilhelm, B., Barabé, F., Gendron, P., Boucher, G., Lemieux, S., Marinier, A., Meloche, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3371 · Cited by 172
Requirement for CDK6 in MLL-rearranged acute myeloid leukemia
Placke, T., Faber, K., Nonami, A., Putwain, S. L., Salih, H. R., Heidel, F. H., Krämer, A., Root, D. E., Barbie, D. A., Krivtsov, A. V., et al. (2014) · Blood · doi:10.1182/blood-2014-02-558114 · Cited by 170
Dimerization of MLL fusion proteins immortalizes hematopoietic cells
Martin, M. E., Milne, T. A., Bloyer, S., Galoian, K., Shen, W., Gibbs, D., Brock, H. W., Slany, R., & Hess, J. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00214-9 · Cited by 168
Biswas, D., Milne, T. A., Basrur, V., Kim, J., Elenitoba-Johnson, K. S. J., Allis, C. D., & Roeder, R. G. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111498108 · Cited by 168
Lineage Switch in MLL‐Rearranged Infant Leukemia Following CD19‐Directed Therapy
Rayes, A., McMasters, R. L., & O'Brien, M. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25953 · Cited by 168
Mann, G., Attarbaschi, A., Schrappe, M., De Lorenzo, P., Peters, C., Hann, I., De Rossi, G., Felice, M., Lausen, B., LeBlanc, T., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273532 · Cited by 164
ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia
Zhu, L., Li, Q., Wong, S. H. K., Huang, M., Klein, B. J., Shen, J., Ikenouye, L., Onishi, M., Schneidawind, D., Buechele, C., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0058 · Cited by 163
Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9
So, C. W., Karsunky, H., Wong, P., Weissman, I. L., & Cleary, M. L. (2004) · Blood · doi:10.1182/blood-2003-10-3722 · Cited by 160
Stumpel, D. J. P. M., Schneider, P., Roon, E. H. J. V., Boer, J. M., Lorenzo, P. D., Valsecchi, M. G., de Menezes, R. X., Pieters, R., & Stam, R. W. (2009) · Blood · doi:10.1182/blood-2009-06-227660 · Cited by 158
Benito, J. M., Godfrey, L., Kojima, K., Hogdal, L. J., Wunderlich, M., Geng, H., Marzo, I., Harutyunyan, K. G., Golfman, L. S., North, P. S., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.12.003 · Cited by 158
Tomizawa, D., Koh, K., Sato, T., Kinukawa, N., Morimoto, A., Isoyama, K., Kosaka, Y., Oda, T., Oda, M., Hayashi, Y., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404903 · Cited by 153
Whitman, S. P., Liu, S., Vukosavljevic, T., Rush, L. J., Yu, L., Liu, C., Klisovic, M. I., Maharry, K. S., Guimond, M., Strout, M. P., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0204 · Cited by 153
Bhatla, T., Wang, J., Morrison, D. J., Raetz, E. A., Burke, M. J., Brown, P. A., & Carroll, W. L. (2012) · Blood · doi:10.1182/blood-2012-01-401687 · Cited by 145
Wilkinson, A. C., Ballabio, E., Geng, H., North, P. S., Tapia, M. C., Kerry, J., Biswas, D., Roeder, R. G., Allis, C. D., Melnick, A. M., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2012.12.016 · Cited by 140
The Histone Methyltransferase Activity of MLL1 Is Dispensable for Hematopoiesis and Leukemogenesis
Mishra, B. P., Zaffuto, K. M., Artinger, E. L., Org, T., Mikkola, H. K. A., Cheng, C., Djabali, M., & Ernst, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.015 · Cited by 137
Tumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ gene
Dobson, C., Warren, A. J., Pannell, R., Forster, A. M., & Rabbitts, T. H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.843 · Cited by 137
Andersen, M. K., Christiansen, D. H., Jensen, B. A., Ernst, P., Hauge, G., & Pedersen-Bjergaard, J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03000.x · Cited by 136
Ma, Q., Alder, H., Nelson, K. K., Chatterjee, D., Gu, Y., Nakamura, T., Canaani, E., Croce, C. M., Siracusa, L. D., & Buchberg, A. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.6350 · Cited by 135
Prasad, R., Yano, T., Sorio, C., Nakamura, T., Rallapalli, R., Gu, Y., Leshkowitz, D., Croce, C. M., & Canaani, E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12160 · Cited by 133
Klaus, C. R., Iwanowicz, D., Johnston, D., Campbell, C. T., Smith, J. J., Moyer, M. P., Copeland, R. A., Olhava, E. J., Scott, M. P., Pollock, R. M., et al. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214577 · Cited by 131
Kampa-Schittenhelm, K. M., Heinrich, M. C., Akmut, F., Döhner, H., Döhner, K., & Schittenhelm, M. M. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-19 · Cited by 125
Schafer, E. S., Irizarry, R. A., Negi, S., McIntyre, E., Small, D., Figueroa, M. E., Melnick, A. M., & Brown, P. A. (2010) · Blood · doi:10.1182/blood-2009-09-243634 · Cited by 122
Histone H2B ubiquitin ligase RNF20 is required for MLL -rearranged leukemia
Wang, E., Kawaoka, S., Yu, M., Shi, J., Ni, T., Yang, W., Zhu, J., Roeder, R. G., & Vakoc, C. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301045110 · Cited by 121
Ma, C., & Staudt, L. M. (1996) · Blood · doi:10.1182/blood.v87.2.734.bloodjournal872734 · Cited by 120
Shi, J., Wang, E., Zuber, J. A., Rappaport, A., Taylor, M. J., Johns, C., Lowe, S. W., & Vakoc, C. R. (2012) · Oncogene · doi:10.1038/onc.2012.110 · Cited by 119
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Gilan, O., Lam, E. Y. N., Becher, I., Lugo, D., Cannizzaro, E., Joberty, G., Ward, A., Wiese, M., Fong, C. Y., Ftouni, S., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3249 · Cited by 119
Stubbs, M. C., Kim, Y., Krivtsov, A. V., Wright, R. D., Feng, Z., Agarwal, J., Kung, A. L., & Armstrong, S. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404951 · Cited by 117
Baker, A., Gregory, G. P., Verbrugge, I., Kats, L. M., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J. A., Shortt, J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1070 · Cited by 117
Smith, L., Yeung, J., Zeisig, B. B., Popov, N., Huijbers, I. J., Barnes, J. L., Wilson, A., Taskesen, E., Delwel, R., Gil, J., et al. (2011) · Cell stem cell · doi:10.1016/j.stem.2011.05.004 · Cited by 113
The MLL partial tandem duplication in acute myeloid leukaemia
Bäsecke, J., Whelan, J. T., Griesinger, F., & Bertrand, F. E. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06301.x · Cited by 109
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
Feng, Z., Yao, Y., Zhou, C., Chen, F., Wu, F., Wei, L., Liu, W., Dong, S., Redell, M. S., Mo, Q., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0252-7 · Cited by 108
Driessen, E. M. C., Roon, E. H. J. V., Spijkers-Hagelstein, J. A. P., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.067983 · Cited by 107
Brown, P. A., Levis, M. J., McIntyre, E., Griesemer, M., & Small, D. (2006) · Leukemia · doi:10.1038/sj.leu.2404277 · Cited by 103
Dreyer, Z. E., Dinndorf, P. A., Camitta, B. M., Sather, H. N., La, M., Devidas, M., Hilden, J. M., Heerema, N. A., Sanders, J. E., McGlennen, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8938 · Cited by 99
Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3)
Dreyer, Z. E., Hilden, J. M., Jones, T. L., Devidas, M., Winick, N. J., Willman, C. L., Harvey, R. C., Chen, I., Behm, F. G., Pullen, J., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25322 · Cited by 96
A role for MEIS1 in MLL-fusion gene leukemia
Kumar, A. R., Li, Q., Hudson, W. A., Chen, W., Sam, T. N., Yao, Q., Lund, E. A., Wu, B., Kowal, B. J., & Kersey, J. H. (2008) · Blood · doi:10.1182/blood-2008-06-163287 · Cited by 96
MLL fusion partners AF4 and AF9 interact at subnuclear foci
Erfurth, F. E., Hemenway, C. S., de Erkenez, A. C., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403200 · Cited by 94
富澤, 大. (2010) · Medical Entomology and Zoology · Cited by 93
Davids, M. S., Seymour, J. F., Gerecitano, J. F., Kahl, B. S., Pagel, J. M., Wierda, W. G., Anderson, M. A., Rudersdorf, N. K., Gressick, L. A., Montalvo, N. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8522 · Cited by 92
The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79
Chen, S., Yang, Z., Wilkinson, A. W., Deshpande, A. J., Sidoli, S., Krajewski, K., Strahl, B. D., Garcia, B. A., Armstrong, S. A., Patel, D. J., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.08.019 · Cited by 91
The mixed lineage leukemia fusion partner AF9 binds specific isoforms of the BCL-6 corepressor
Srinivasan, R. S., de Erkenez, A. C., & Hemenway, C. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206361 · Cited by 89
Dietary flavonoids induce MLL translocations in primary human CD34+ cells
van Doorn-Khosrovani, S. B. V. W., Janssen, J. W. H., Maas, L. M., Godschalk, R., Nijhuis, J. G., & van Schooten, F. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm102 · Cited by 89
Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL
Stubbs, M. C., Kim, W.-I., Bariteau, M. A., Davis, T. N., Vempati, S., Minehart, J. C., Witkin, M. D., Qi, J., Krivtsov, A. V., Bradner, J. E., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1290 · Cited by 88
Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements
Rozovskaia, T., Ravid-Amir, O., Tillib, S. V., Getz, G. A., Feinstein, E., Agrawal, H., Nagler, A., Rappaport, E. F., Issaeva, I., Matsuo, Y., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1132115100 · Cited by 87
Stumpel, D. J. P. M., Schneider, P., Seslija, L., Osaki, H., Williams, O., Pieters, R., & Stam, R. W. (2011) · Leukemia · doi:10.1038/leu.2011.278 · Cited by 86
Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells
Yuan, J., Takeuchi, M., Negishi, M., Oguro, H., Ichikawa, H., & Iwama, A. (2011) · Leukemia · doi:10.1038/leu.2011.85 · Cited by 86
EVI1 is critical for the pathogenesis of a subset of MLL-AF9–rearranged AMLs
Bindels, E. M., Havermans, M., Lugthart, S., Erpelinck-Verschueren, C. A. J., Wocjtowicz, E., Krivtsov, A. V., Rombouts, E. J. C., Armstrong, S. A., Taskesen, E., Haanstra, J. R., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393827 · Cited by 86
MLLT3 Regulates Early Human Erythroid and Megakaryocytic Cell Fate
Pina, C., May, G. E., Soneji, S., Hong, D., & Enver, T. (2008) · Cell stem cell · doi:10.1016/j.stem.2008.01.013 · Cited by 82
Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
Kuo, H.-P., Wang, Z., Lee, D., 岩崎, 正., Duque‐Afonso, J., Wong, S. H. K., Lin, C.-H., Figueroa, M. E., Su, J., Lemischka, I. R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.019 · Cited by 80
Drynan, L. F., Pannell, R., Forster, A. M., Chan, N. M. M., Cano, F., Daser, A., & Rabbitts, T. H. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600760 · Cited by 78
Cooper, T. M., Cassar, J., Eckroth, E., Malvar, J., Sposto, R., Gaynon, P. S., Chang, B. H., Gore, L., August, K. J., Pollard, J. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1998 · Cited by 78
Hemenway, C. S., de Erkenez, A. C., & Gould, G. C. D. (2001) · Oncogene · doi:10.1038/sj.onc.1204478 · Cited by 77
Borkin, D., Pollock, J., Kempińska, K., Purohit, T., Li, X., Wen, B., Zhao, T., Miao, H. Z., Shukla, S., He, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01305 · Cited by 77
Gruhn, B., Naumann, T., Gruner, D., Walther, M., Wittig, S., Becker, S., Beck, J. F., & Sonnemann, J. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.07.016 · Cited by 73
Butler, L. H., Slany, R. K., Cui, X., Cleary, M. L., & Mason, D. Y. (1997) · Blood · doi:10.1182/blood.v89.9.3361 · Cited by 72
Marschalek, R. (2015) · Annals of Laboratory Medicine · doi:10.3343/alm.2016.36.2.85 · Cited by 71
Yun, S., Vincelette, N. D., Abraham, I. L., Robertson, K. D., Fernández-Zapico, M. E., & Patnaik, M. M. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0233-2 · Cited by 70
Loss of MLL PHD Finger 3 Is Necessary for MLL-ENL–Induced Hematopoietic Stem Cell Immortalization
Chen, J., Santillan, D. A., Koonce, M., Wei, W., Luo, R. T., Thirman, M. J., Zeleznik‐Le, N. J., & Dı́az, M. O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6514 · Cited by 68
The Biology and Targeting of FLT3 in Pediatric Leukemia
Annesley, C., & Brown, P. A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00263 · Cited by 67
The ENL moiety of the childhood leukemia-associated MLL–ENL oncoprotein recruits human Polycomb 3
García-Cuéllar, M.-P., Zilles, O., Schreiner, S., Birke, M. T., Winkler, T., & Slany, R. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204108 · Cited by 67
Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies
Matthews, G. M., Mehdipour, P., Cluse, L. A., Falkenberg, K. J., Wang, E., Roth, M., Santoro, F., Vidacs, E., Stanley, K. L., House, C. M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-632984 · Cited by 65
Urtishak, K. A., Edwards, A. Y. Z., Wang, L., Hudome, A. R., Robinson, B. W., Barrett, J. S., Cao, K., Cory, L. A., Moore, J. S., Bantly, A. D., et al. (2013) · Blood · doi:10.1182/blood-2012-04-425033 · Cited by 64
Menin regulates the function of hematopoietic stem cells and lymphoid progenitors
Maillard, I. P., Chen, Y.-X., Friedman, A. D., Yang, Y., Tubbs, A., Shestova, O. E., Pear, W. S., & Hua, X. (2008) · Blood · doi:10.1182/blood-2008-01-135012 · Cited by 58
Jones, C. L., Bhatla, T., Blum, R., Wang, J., Paugh, S. W., Wen, X., Bourgeois, W., Bitterman, D. S., Raetz, E. A., Morrison, D. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.569889 · Cited by 57
MLL fusion-driven activation ofCDK6potentiates proliferation inMLL-rearranged infant ALL
der Linden, M. V., Willekes, M., Roon, E. H. J. V., Seslija, L., Schneider, P., Pieters, R., & Stam, R. W. (2014) · Cell Cycle · doi:10.4161/cc.27757 · Cited by 56
Kersey, J., Wang, D., & Oberto, M. (1998) · Leukemia · doi:10.1038/sj.leu.2401148 · Cited by 55
Maethner, E., García-Cuéllar, M.-P., Breitinger, C., Takáčová, S., Divoký, V., Hess, J. L., & Slany, R. K. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.03.038 · Cited by 55
Abundant anti‐apoptotic BCL‐2 is a molecular target in leukaemias with t(4;11) translocation
Robinson, B. W., Behling, K. C., Gupta, M., Zhang, A. Y., Moore, J. S., Bantly, A. D., Willman, C. L., Carroll, A. J., Adamson, P. C., Barrett, J. S., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07100.x · Cited by 55
Scharf, S., Zech, J., Bursen, A., Schraets, D., Oliver, P. L., Kliem, S., Pfitzner, E., Gillert, E., Dingermann, T., & Marschalek, R. (2006) · Oncogene · doi:10.1038/sj.onc.1209948 · Cited by 54
Okuda, H., Kanai, A., Ito, S., Matsui, H., & Yokoyama, A. (2015) · Nature Communications · doi:10.1038/ncomms9869 · Cited by 53
He, S., Malik, B., Borkin, D., Miao, H. Z., Shukla, S. K., Kempińska, K., Purohit, T. A., Wang, J., Chen, L., Parkin, B. L., et al. (2015) · Leukemia · doi:10.1038/leu.2015.144 · Cited by 51
Acute lymphoblastic leukemia in infancy
Silverman, L. B. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21352 · Cited by 51
Manara, E., Baron, E., Tregnago, C., Aveic, S., Bisio, V., Bresolin, S., Masetti, R., Locatelli, F., Basso, G., & Pigazzi, M. (2014) · Blood · doi:10.1182/blood-2013-09-525741 · Cited by 51
Stein, E. M., Garcia‐Manero, G., Rizzieri, D. A., Tibes, R., Berdeja, J. G., Jongen‐Lavrencic, M., Altman, J. K., Döhner, H., Thomson, B. G., Blakemore, S. J., et al. (2015) · Blood · doi:10.1182/blood.v126.23.2547.2547 · Cited by 48
Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4
Liu, H., Westergard, T. D., Cashen, A. F., Piwnica-Worms, D. R., Kunkle, L., Vij, R., Pham, C. G., DiPersio, J. F., Cheng, E. H. Y., & Hsieh, J. J.-D. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.008 · Cited by 46
Kerstjens, M., Driessen, E. M. C., Willekes, M., Pinhanços, S., Schneider, P., Pieters, R., & Stam, R. (2016) · OncoTarget · doi:10.18632/oncotarget.11730 · Cited by 46
García-Cuéllar, M.-P., Büttner, C., Bartenhagen, C., Dugas, M., & Slany, R. K. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.018 · Cited by 45
Valentine, M. C., Linabery, A. M., Chasnoff, S. E., Hughes, A. E. O., Mallaney, C., Sanchez, N., Giacalone, J., Heerema, N. A., Hilden, J. M., Spector, L. G., et al. (2013) · Leukemia · doi:10.1038/leu.2013.367 · Cited by 44
Finke, J., Schmoor, C., Bertz, H., Marks, R., Wäsch, R., Zeiser, R., & Hackanson, B. W. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.338 · Cited by 42
Insights in dynamic kinome reprogramming as a consequence of MEK inhibition in MLL-rearranged AML
Kampen, K. R., ter Elst, A., Mahmud, H., Scherpen, F. J. G., Diks, S. H., Peppelenbosch, M. P., de Haas, V., Guryev, V., & de Bont, E. S. J. M. (2013) · Leukemia · doi:10.1038/leu.2013.342 · Cited by 41
Ueda, K., Yoshimi, A., Kagoya, Y., Nishikawa, S., Márquez, V. E., Nakagawa, M. M., & Kurokawa, M. (2014) · Cancer Science · doi:10.1111/cas.12386 · Cited by 39
The essential role of acetyllysine binding by the YEATS domain in transcriptional regulation
Andrews, F. H., Shanle, E. K., Strahl, B. D., & Kutateladze, T. G. (2016) · Transcription · doi:10.1080/21541264.2015.1125987 · Cited by 38
Inukai, T., Zhang, X., Goto, M., Hirose, K., Uno, K., Akahane, K., Nemoto, A., Goi, K., Sato, H., Takahashi, K., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404429 · Cited by 37
Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways
Yokoyama, A., Ficara, F., Murphy, M., Meisel, C., Naresh, A., Kitabayashi, I., & Cleary, M. L. (2011) · Journal of Cell Science · doi:10.1242/jcs.080523 · Cited by 37
Acute Myeloid Leukemia With t(9;11)(p21–22;q23)
Chandra, P., Luthra, R., Zuo, Z., Yao, H., Ravandi, F., Reddy, N., Garcia‐Manero, G., Kantarjian, H. M., & Jones, D. M. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpgii1tt4nyogi · Cited by 36
Lubecka, K., Kaufman‐Szymczyk, A., Stefañska, B., Cebula‐Obrzut, B., Smolewski, P., & Fabianowska‐Majewska, K. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.021 · Cited by 35
Li, Q., Frestedt, J. L., & Kersey, J. H. (1998) · Blood · doi:10.1182/blood.v92.10.3841 · Cited by 35
Hale, G., Heslop, H., Bowman, L., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701962 · Cited by 34
Secondary mutations in t(4;11) leukemia patients
Prelle, C., Bursen, A., Dingermann, T., & Marschalek, R. (2012) · Leukemia · doi:10.1038/leu.2012.365 · Cited by 30
Cruickshank, M. N., Ford, J., Cheung, L. C., Heng, J., Singh, S., Wells, J. E., Failes, T. W., Arndt, G. M., Smithers, N. N., Prinjha, R. K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.165 · Cited by 30
Cited by
Boija, A., Klein, I. A., Sabari, B. R., Dall’Agnese, A., Coffey, E. L., Zamudio, A. V., Li, C. H., Shrinivas, K., Manteiga, J. C., Hannett, N. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.042 · Cited by 1,815
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Xu, X., Sun, Q., Liang, X., Chen, Z., Zhang, X., Zhou, X., Li, M., Tu, H., Liu, Y., Tu, S., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02664 · Cited by 347
Biomolecular Condensates and Cancer
Boija, A., Klein, I. A., & Young, R. A. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.003 · Cited by 327
Epigenetic heterogeneity in cancer
Guo, M., Peng, Y., Gao, A., Du, C., & Herman, J. G. (2019) · Biomarker Research · doi:10.1186/s40364-019-0174-y · Cited by 270
Metadata
- Authors
- Winters, A. C., & Bernt, K. M.
- Venue
- Frontiers in Pediatrics
- Publisher
- Frontiers Media SA
- Published
- 2017-02-09
- Volume
- 5
- Pages
- 4-4
- ISSN
- 2296-2360 (ISSN-L)
- OpenAlex
- W2587240909
- Cited by
- 405
- References
- 208
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.